God is from Madrid isn’t he?

Tuchel. Absolute 🤡

No no no no no

This trade is literally printing money

𝗠𝗕𝟭𝟵𝟰: 𝗪𝗼𝗼𝗹𝘄𝗼𝗿𝘁𝗵𝘀, 𝗕𝗲𝗿𝗸𝘀𝗵𝗶𝗿𝗲 𝗛𝗮𝘁𝗵𝗮𝘄𝗮𝘆'𝘀 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 & 𝗦𝘁𝗮𝗿𝗯𝘂𝗰𝗸𝘀

L I N K I N B I O

Sam North To make a really rich lamb jus.

We’ve all done this or bought a stock because your mate says it’s a winner, right?!

Sam North To be fair Goals at one stage was amazing 😂

I bought Unity as some analysts at a research firm I was doing work wrote a piece that had me absolutely convinced 🤦‍♂️ it is down significantly since then

Adele the 🐐

What is your most stupid reason for buying a stock?

I’ll start.

I bought Goals Soccer Centres PLC because England were having a good World Cup in 2018 and thought more people would play football 😂

This level of petty.....love it

🎢Taking on the earnings season rollercoaster?

Our Popular Investor Neža Molk shares a crucial tip: it's all about rebalancing when stocks fluctuate post-earnings to keep your investments aligned with your goals and risk tolerance🔄

Learn more👇

This 👇

In this episode, Sam North (Sam North) discuss trading and investing while driving from eToro 's office in Canary Wharf. They talk about the importance of planning and strategy in trading, the benefits of using a virtual account to practice: youtube.com/watch?v=neBIqr…

FERRARI HALTED AFTER FALLING AS MUCH AS 5%

🎙Tune into The Daily Voice for insights with our Global Markets Strategist Ben Laidler, who unpacks Q1's unique earnings recovery and previews $DIS's results, focusing on parks and streaming. Plus, insights on $TSLA and $META

All in under 5 minutes👇
etoro.tw/3UscZvL

ANOTHER INTERESTING EARNINGS WEEK!

MON:
FMC
Palantir
Vertex Pharma.

TUE:
Disney
Celsius
Crocs

WED:
Toyota
Uber
Airbnb
Shopify

THU:
Roblox
Warner Bros
Fiverr

FRI:
Enbridge
CRH

📍 Emirates

📍 Breakfast at the Arsenal

King of the day: AMGEN
(up 13% today)

Revenue: $7.4 billion an increase of 22% in Q1 compared to Q1 2023.

Non-GAAP EPS: $3.96 vs. $3.89 expected.

But what really convinced the investors was an update on the obesity drug MariTide, for which the Phase II trial was completed.